September 24, 2019

Christian Schade
Chief Executive Officer
Aprea Therapeutics, Inc.
535 Boylston Street
Boston, MA 02116

       Re: Aprea Therapeutics, Inc.
           Amendment No. 1 to Registration Statement on Form S-1
           Filed September 23, 2019
           File No. 333-233662

Dear Mr. Schade:

      We have reviewed your amended registration statement and have the
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
circumstances or do not believe an amendment is appropriate, please tell us why
in your

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Amendment No. 1 to Registration Statement on Form S-1

Exhibits and financial statement schedules
Exhibit 10.3, page II-4

1.     We note your disclosure in Exhibit 10.3 that "[c]ertain information in
this document has
       been omitted and filed separately with the Securities and Exchange
       Confidential treatment has been requested with respect to the omitted
portions." If you
       intend to redact information pursuant to Item 601(b) of Regulation S-K,
please revise the
       language in Exhibit 10.3 to state that certain identified information
has been excluded
       from the exhibit because it is both (i) not material and (ii) would be
competitively harmful
       if publicly disclosed.
 Christian Schade
Aprea Therapeutics, Inc.
September 24, 2019
Page 2

       You may contact Keira Nakada at 202-551-3659 or Kevin Vaughn at
202-551-3494 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Sonia Bednarowski at 202-551-3666 or Dietrich King at 202-551-8071 with
any other

FirstName LastNameChristian Schade                        Sincerely,
Comapany NameAprea Therapeutics, Inc.
                                                          Division of
Corporation Finance
September 24, 2019 Page 2                                 Office of Healthcare
& Insurance
FirstName LastName